COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCER

被引：1
|
作者：
Tikhonova, I [1 ]
Hoyle, M. [1 ]
Snowsill, T. [1 ]
Crathorne, L. [1 ]
Varley-Campbell, J. [1 ]
Peters, J. [1 ]
Briscoe, S. [1 ]
Bond, M. [1 ]
Huxley, N. [1 ]
机构：
[1] Univ Exeter, Exeter, Devon, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1612
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN113
引用
收藏
页码：A154 / A154
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
    Han, Jiaqi
    Xiao, Desheng
    Tan, Chongqing
    Zeng, Xiaohui
    Hu, Huabin
    Zeng, Shan
    Jiang, Qin
    She, Longjiang
    Yao, Linli
    Li, Li
    Tang, Lanhua
    Ma, Jian
    Huang, Jin
    Shen, Liangfang
    CANCER CONTROL, 2020, 27 (01)
  • [32] A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US
    Graham, Christopher N.
    Christodoulopoulou, Alexandra
    Knox, Hediyyih N.
    Sabatelli, Lorenzo
    Hechmati, Guy
    Garawin, Tamer
    Strickler, John H.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (11) : 1075 - 1083
  • [33] COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: A MODELLING APPROACH FOR THE UK
    Garrell, D.
    Griebsch, I
    Samyshkin, Y.
    VALUE IN HEALTH, 2008, 11 (06) : A465 - A465
  • [34] COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: DESCRIPTION OF A NICE SUBMISSION
    Eggington, S. G.
    Garrell, D.
    Griebsch, I
    Samyshkin, Y.
    VALUE IN HEALTH, 2009, 12 (07) : A279 - A279
  • [35] Impact of tumour RAS/BRAF status in a first-line study of panitumumab plus FOLFIRI in patients with metastatic colorectal cancer
    Karthaus, Meinolf
    Hofheinz, Ralf-Dieter
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Fernebro, Eva
    Oliner, Kelly S.
    Boedigheimer, Michael
    Twomey, Brian
    Zhang, Ying
    Demonty, Gaston
    Koehne, Claus-Henning
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1215 - 1222
  • [36] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB plus MFOLFOX OVER BEVACIZUMAB plus MFOLFOX AS A FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER PATIENTS WITH WILD-TYPE RAS IN GREECE
    Kourlaba, G.
    Boukovinas, I
    Saridaki, Z.
    Papagiannopoulou, V
    Tritaki, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A633 - A633
  • [37] Cost-effectiveness of cetuximab plus FOLFIRI versus bevacizumab plus FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
    Van Oostrum, Ilse
    Hu Yannan
    Yuan Zijiao
    Schlichting, Michael
    Tao Libo
    Pescott, Chris P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [38] Genomic alterations on first-line panitumumab plus FOLFIRI in metastatic colorectal cancer
    Avallone, Antonio
    Giuliani, Francesco
    Nasti, Guglielmo
    Montesarchio, Vincenzo
    Santabarbara, Giuseppe
    Leo, Silvana
    Malapelle, Umberto
    Rosati, Gerardo
    Lotesoriere, Claudio
    Tamburini, Emiliano
    Colombo, Alfredo
    Pepe, Francesco
    Cardone, Claudia
    Leone, Alessandra
    Vitagliano, Carlo
    Russo, Gianluca
    Troncone, Giancarlo
    Giannarelli, Diana
    De Stefano, Alfonso
    Budillon, Alfredo
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Effectiveness and Safety of Cetuximab as First-line Treatment in the Elderly with Metastatic Colorectal Cancer from the EREBUS Cohort
    Fourrier-Reglat, Annie
    Noize, Pernelle
    Rouyer, Magali
    Smith, Denis
    Francois, Eric
    Monnereau, Alain
    Balestra, Aurelie
    Jove, Jeremy
    Lassalle, Regis
    Moore, Nicholas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 310 - 310
  • [40] Effectiveness and Safety of Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer According to Frailty in the EREBUS Study
    Gouverneur, Amandine
    Coutureau, Juliette
    Rouyer, Magali
    Smith, Denis
    Francois, Eric
    Monnereau, Alain
    Balestra, Aurelie
    Jove, Jeremy
    Lassalle, Regis
    Moore, Nicholas
    Fourrier-Reglat, Annie
    Noize, Pernelle
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 520 - 521
12345